---
title: Menin inhibitors in the treatment of acute myeloid leukemia
date: '2024-12-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39719041/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241225170554&v=2.18.0.post9+e462414
source: Blood
description: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy
  characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite
  advances in treatment, AML remains challenging to cure, particularly in patients
  with specific genetic abnormalities. Menin inhibitors have emerged as a promising
  therapeutic approach, targeting key genetic drivers of AML such as KMT2A rearrangements
  and NPM1 mutations. Here, we review the clinical value of menin inhibitors, highlighting
  ...
disable_comments: true
---
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities. Menin inhibitors have emerged as a promising therapeutic approach, targeting key genetic drivers of AML such as KMT2A rearrangements and NPM1 mutations. Here, we review the clinical value of menin inhibitors, highlighting ...